All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
25 results for "Cancer" and "Brain and Spine Cancers" and "Lung"
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors
This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)
Phase 1/2 open-label, multicenter study to evaluate the safety, PK, and pharmacodynamics of HPN328 in patients with SCLC or with advanced solid tumors associated with expression of DLL3. This study will be divided into 2 parts: Dose Escalation (Part 1) and Expansion (Part 2).
Protocol No
HARPOON-HPN328-4001
Sub Category
A Phase 1 dose escalation study to assess safety and efficacy of ADP-A2M4CD8 as monotherapy or in combination with Nivolumab in HLA-A2+ subjects with MAGE-A4 positive tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Protocol No
ADP-0055-001-MAGE-A4-SURPASS
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Protocol No
JOUNCE-JTX-8064-101
A Phase I Study of GNX102 in Patients with Advanced Solid Tumors
This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Protocol No
GLYCONEX-GNX-001
Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors
To assess the safety and tolerability of ociperlimab in combination with tislelizumab in
patients with advanced solid tumors. Then to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of ociperlimab in combination with tislelizumab, and determine the recommended Phase 2 dose (RP2D) of ociperlimab in combination with
tislelizumab.
patients with advanced solid tumors. Then to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of ociperlimab in combination with tislelizumab, and determine the recommended Phase 2 dose (RP2D) of ociperlimab in combination with
tislelizumab.
Protocol No
BEIGENE-BGB-900-105
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Testing the Use of Combination Immunotherapy
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Protocol No
SWOG-S1800D-ALT-803
Sub Category
A First-in-Human, Phase 1-2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Sub Category
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Phase III trial to determine if treatment with Sacituzumab Govitecan can prolong survival in patients with non-small cell lung cancer who progressed on standard therapy
Protocol No
GILEAD-GS-US-577-6153
Sub Category
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer
Protocol No
NRG-LU007
Sub Category
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Protocol No
ALLIANCE-ALCHEMIST-A081801
Sub Category
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Protocol No
ECOG-ALCHEMIST-E4512
Sub Category
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
Protocol No
ECOG-EA5182
Sub Category
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer
Protocol No
ALLIANCE-A171901
Sub Category
Randomized, Open Label Phase 3 Study of SAR408701 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-Small Cell Lung Cancer Patients with CEACAM5 Positive Tumors
Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (CARMEN-LC03)
Protocol No
SANOFI-EFC15858
Sub Category
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer
With Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No
ECOG-EA5181
Sub Category
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804